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ABSTRACT
Pregnancy is associated with numerous changes affecting all organs. Ophthalmological changes in pregnant women are 
most often physiological and resolve spontaneously after delivery. However, the possibility of progression of previously 
diagnosed ophthalmic diseases or the occurrence of ophthalmological complications in the course of diseases characteristic 
for pregnancy should always be considered.
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INTRODUCTION
Ophthalmological changes during pregnancy are usu-
ally physiological, temporary and do not require any treat-
ment. However, in some women with previously diagnosed 
glaucoma or diabetic retinopathy there is a great risk of 
illness progression. Also, some medical conditions typi-
cal for pregnancy, such as preeclampsia, eclampsia and 
Sheehan’s syndrome, may manifest with ophthalmological 
symptoms.
The main aim of this review is to present possible 
pathological changes ophthalmological diseases progres-
sion that may occur throughout pregnancy. Moreover, 
we would like to discuss possible treatment methods of 
some disorders and the ophthalmological indications for 
caesarean section.
Glaucoma and pregnancy
Glaucoma is neuropathy of the optic nerve character-
ized by typical changes in the visual field and optic nerve 
head that usually occur in people over 40 years of age but 
may present in younger patients. Glaucoma treatment 
is based on pharmacotherapy or surgical techniques, 
including laser treatment. The only modifiable risk factor 
in glaucoma patients is the intraocular pressure (IOP). Per-
sisting high values of IOP lead to glaucoma progression. 
In many cases pharmacotherapy is adequate to maintain 
the target IOP. During pregnancy the IOP decreases but 
many women with diagnosed glaucoma still require fur-
ther treatment.
Glaucoma pharmacotherapy
Prostaglandins, beta blockers, alpha-2 agonists, carbonic 
anhydrase inhibitors, miotics and osmotic agents are used 
in glaucoma pharmacotherapy. Most of them are applied 
topically to the conjunctival sac. To obtain maximum local 
treatment and minimize the general adverse effects, proper 
application is essential. Inserting only one drop of antiglau-
coma drug, closing the eye for 3–5 minutes and compressing 
the lacrimal puncta all help to reduce systemic absorption.
Brimonidine is one of the alpha-2 agonists classified 
as category B by the Food and Drug Administration (FDA). 
This drug may be used during pregnancy but therapy with 
brimonidine should be ceased before labour because it pen-
etrates through the blood–brain barrier, which can cause 
apnoea in the newborn [1].
Among the beta blockers used in glaucoma pharma-
cotherapy there are several that are non-selective, such as 
timolol, carteolol, levobunolol, metipranolol and beta-1-se-
lective betaxolol, all of which are classified as category C by 
the FDA. There are limited reports about the impact of locally 
administered beta blockers on the foetus, however extreme 
caution must be exercised, especially in the first trimester, 
due to their teratogenic effect. Moreover, if given systemi-
cally during the second or third trimester, beta blockers 
may lead to intrauterine growth restriction (IUGR), as well 
as dysfunction of the newborn’s cardiovascular and nerv-
ous system. It is assumed that even small doses of timolol 
used by pregnant women lead to permanent changes in 
the heart’s electrical conduction system [2]. Furthermore, 
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breathing disorders were observed in newborns whose 
mothers used timolol during pregnancy [3].
Prostaglandin analogues (travoprost, latanoprost, bi-
matoprost, tafluprost) are very effective hypotensive drugs 
commonly used in glaucoma therapy, although their usage 
is not recommended in pregnant women. An increased 
number of miscarriages were observed, compared to a con-
trol group, when the prostaglandins were used topically in 
animal research [4]. Prostaglandin analogues may increase 
uterine tonus and stimulate uterine contractions, leading 
to miscarriage or premature labour.
Carbonic anhydrase inhibitors can be used both topi-
cally and systemically (orally or intravenously). Brinzolamide 
and acetazolamide are classified as category C by the FDA. 
Animal testing with brinzolamide revealed the presence 
of additional cranial bones in rabbit foetuses, however the 
dose was higher than that used in antiglaucoma eye drops 
[5]. Acetazolamide can be used topically, orally or intrave-
nously. During animal testing with acetazolamide, front 
extremity defects in rat foetuses were observed after high 
doses [6]. Warsham et al. [7] published the case report of 
a newborn with sacrococcygeal teratoma whose mother 
used acetazolamide throughout her pregnancy. There is 
also a risk of metabolic disorders in newborns if the mother 
used acetazolamide whilst pregnant [8].
Pilocarpine is quite rarely used in glaucoma treatment, 
mainly for acute angle closure. Like other parasympatho-
mimetic drugs, it is classified as category C by the FDA. In 
animal testing, pilocarpine’s teratogenic action has been 
proved [9].
In order to achieve fast reduction of the IOP, osmotic 
drugs such as mannitol or 85% glycerol solution are com-
monly used. Both drugs are category C and should be used 
during pregnancy only if the benefits overweigh the risks.
Surgical treatment in glaucoma patients
Surgical treatment for glaucoma includes both laser 
and surgical methods.
Laser treatments such as selective laser trabeculoplasty 
(SLT) or YAG-laser iridotomy are possible throughout preg-
nancy. SLT allows the number of antiglaucoma drugs to be 
reduced or, in some cases, eliminated completely. Iridotomy 
is a well-known procedure performed in patients with a nar-
row or closed iridocorneal angle. Laser treatment seems to 
be a safe method for managing glaucoma but both SLT and 
iridotomy require perioperative medication with topical 
drugs, some of which are category C.
If progression in visual field changes is observed despite 
maximal pharmacological treatment with topical drugs, or 
if drops are not well tolerated and cause local or systemic 
side effects, then surgery should be considered. Many of 
the filtration surgeries, such as trabeculectomy, phacotra-
beculectomy and deep sclerectomy, require the use of an-
timetabolites (mitomycin C or 5-fluorouracil) during the 
procedure to achieve a better effect and reduce the risk of 
scarring. Unfortunately, antimetabolites have a teratogenic 
and mutagenic effect on the foetus [10, 11]. It seems that the 
best option is to conduct an operation before any planned 
conception. Other surgical techniques used in advanced 
glaucoma, such as cyclodestruction procedures (cyclocry-
oapplication or the much more popular cyclophotocoagu-
lation), should be preceded by periocular anaesthesia with 
lidocaine or bupivacaine, which may be associated with 
serious side effects in both the mother and child.
Labour and glaucoma
One of the surveys conducted on a group of healthy 
pregnant women revealed a statistically significant increase 
in IOP during labour [12]. Vaginal delivery in women with 
a narrow iridocorneal angle is associated with a high risk of 
acute angle closure [13]. Furthermore, decreased intraocular 
blood flow caused by postpartum haemorrhage is extremely 
dangerous. Caesarean section should be considered in pa-
tients with advanced glaucoma in order to prevent further 
ocular complications.
What are the indications for caesarean section in pa-
tients with glaucoma? According to the Ophthalmologic 
and Obstetrical Consensus on Indications for Delivery by Cae-
sarean Section due to Changes in the Sight Organ, February 
2017 [14], the decision is made by an experienced obste-
trician based on the opinion of an ophthalmologist after 
ophthalmological examination. Patients with advanced 
changes in the visual field caused by glaucoma have a high 
risk of ophthalmological complications if they give birth 
vaginally. Each case should be considered individually after 
appropriate examination and careful analysis of previous 
medical records to determine the potential degree of dis-
ease progression.
Diabetic retinopathy in pregnant women
Gestational diabetes mellitus (GDM) is defined as the 
onset or first diagnosis during pregnancy of glucose intoler-
ance. If diagnosed before conception, the diabetes is defined 
as pregestational diabetes mellitus (PGDM).
GDM does not require monitoring throughout preg-
nancy. In a survey of 107 pregnant women diagnosed with 
GDM, none of the patients developed diabetic retinopathy 
(DR) during pregnancy [15].
However, with PGDM (regardless of type), pregnancy is 
a significant risk factor for DR progression due to many fac-
tors: poor glycaemic control, duration of diabetes, fast nor-
moglycaemia achievement during the first weeks of preg-
nancy, elevated serum levels of growth factors, co-existing 
hypertension or preeclampsia and haemodynamic changes 
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in blood vessels. Improper glycaemic control by a woman of 
conceptual age may lead to DR development before preg-
nancy [16]. Obtaining normoglycaemia decreases the risk 
of miscarriage or congenital defects but, paradoxically, is 
associated with DR progression. The duration of diabetes 
seems to be less relevant compared with the previously 
discussed risk factors. It has been proved that increased 
growth factor serum levels such as IGF-1 cause progression 
of DR despite good glycaemic control [17]. Hypertension is 
critical in DR progression, especially in pregnancy. In one 
cohort study of a group of 154 pregnant women diagnosed 
with both pregestational DR and hypertension, progression 
of retinal changes was observed in 55%. On the other hand, 
in women diagnosed with PGDM but with no hypertension, 
progression of DR occurred in only 25% [18]. Furthermore, 
haemodynamic changes characteristic for pregnancy, such 
as increased cardiac output, increased plasma volume and 
reduced peripheral vascular resistance, affect the retinal 
blood flow. In healthy pregnant women there are mecha-
nisms that maintain a constant blood flow [19] but a hyper-
dynamic blood circulation in pregnant women with PGDM 
can cause further endothelial damage [20].
In 2015 the National Institute of Clinical Excellence 
(NICE) published new guidelines for women with PGDM [21]. 
According to the NICE guidelines all women with previously 
diagnosed diabetes should be informed about potential DR 
progression in the preconception period. Also, women with 
diabetes who are planning a pregnancy should accomplish 
good glycaemic control before conception. Moreover, pa-
tients should be informed about the risk of DR progression 
caused by rapidly achieving normoglycaemia. The authors 
of the NICE 2015 Guidelines advise that the first fundoscopy 
should be conducted after an earlier application of mydriat-
ics (e.g. tropicamide) during the first visit, optimally in the 
10th week of pregnancy, and then also in the 28th week of 
pregnancy. If during the first ophthalmological examination 
there are any symptoms indicating DR, then an additional 
fundoscopy should be conducted between the 16th and 
20th week of pregnancy. The presence of features indicating 
DR are contraindications for rapid glycaemia and glycated 
haemoglobin (HbA1c) optimization. All women with di-
agnosed DR or with any retinal changes due to DR during 
pregnancy should be monitored for six months after labour.
Optimal glycaemic control and proper treatment of pre-
viously diagnosed DR before a planned pregnancy should 
prevent any DR progression that requires treatment. In one 
retrospective study conducted on 540 pregnant women 
with diabetes over a 12-year period, only eight patients 
(1.5%) experienced changes characteristic of proliferative 
retinopathy requiring retinal laser therapy [22]. Decisions 
about laser treatment of the retina in such cases should 
not be delayed because proliferative DR is associated with 
a great risk of complications and the need for extensive 
vitreoretinal surgery.
Diabetic macular oedema (DMO) occurs in a minor 
number of pregnant women with diabetes and subsides 
spontaneously after labour [23]. Co-existing nephropathy 
and hypertension are important risk factors for DMO in 
GDM. Intravitreal injections of anti-vascular endothelial 
growth factor (anti-VEGF) — ranibizumab, bevacizumab, 
aflibercept – are widely used in DMO treatment, although 
animal tests demonstrate adverse effects on embryo and 
foetus, therefore they should not be used during pregnancy.
According to the NICE Guidelines 2015, uncomplicated 
DR is not a direct indication for spontaneous delivery [21]. 
On the other hand, the authors of the Ophthalmologic and 
Obstetrical Consensus on Indications for Delivery by Caesar-
ean Section due to Changes in the Sight Organ recommend 
that ending pregnancy by caesarean section should be 
considered in the following cases: the presence of recurrent 
vitreous haemorrhage due to DR; the presence of neovascu-
larization at the disk (NVD) or neovascularization elsewhere 
(NVE), which probably will not disappear (after treatment or 
spontaneously) before delivery; and the presence of trac-
tional retinal detachment that develops and progresses 
throughout pregnancy [14].
Central serous retinopathy
Central serous retinopathy (CSR) is an idiopathic disease 
characterized by retinal detachment in the macular region 
secondary to focal defect of the retinal pigment epithelium. 
CSR is typical for males aged 20–50 years but it can also be 
observed in females. The risk factors of CSR are stress, steroid 
therapy, Cushing syndrome, hypertension and gestation. 
Presented symptoms such as blurry vision, central scotoma, 
micropsia and metamorphopsia are usually unilateral.
In one prospective study it has been estimated that 
CSR affects 0.44% of pregnant women [24]. The best diag-
nostic method to confirm CSR is fluorescein angiography, 
however optical coherence tomography (OCT) seems to 
be a safer option.
CSR is usually self-limiting, with all symptoms generally 
resolving within three months. However, if CSR symptoms 
do not resolve there are a few therapeutic methods that 
might be considered, such as laser therapy or pharmaco-
logical treatment (using spironolactone, eplerenone, finas-
teride, carbonic anhydrase inhibitor or acetylsalicylic acid) 
[25]. When choosing a specific therapy for CSR in pregnant 
women, the risk of foetal defects must be considered.
Myopia
Myopia is a common refractive error caused by both 
genetic and environmental factors and is classified as low 
(less than –2 dioptre), moderate (–2 to –6 dioptre) or high 
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(more than –6 dioptre). In a survey, Fernandez-Montero 
et al. [26] found that pregnancy is a risk factor for myopia 
development or progression. Another survey conducted 
by Piazzello [27] found that a myopic shift was observed 
in pregnant women but that it returned to pre-pregnancy 
values after labour.
Although high myopia is a risk factor for retinal detach-
ment, it is not a contraindication for spontaneous vaginal 
delivery. Neri et al. [28] examined 50 women with myopia 
ranging from –4,5 to –15 dioptre, with each patient under-
going fundoscopy before and after labour; none of them 
had a retinal detachment or tear caused by the delivery.
In some patients with degenerative myopia, choroidal 
neovascularization may develop and caesarean section 
should be performed [14]; otherwise, even high myopia 
should not be considered an indication for caesarean sec-
tion.
Papilloedema during pregnancy
Papilloedema is always a diagnostic challenge and is 
defined as optic disc oedema secondary to increased intrac-
ranial pressure. Optic disc swelling may be caused by both 
life-threatening and non-life-threatening conditions and 
requires complex diagnostics. There are many causes of pap-
illoedema in pregnant women, some of which are related 
to the pregnancy. For a differential diagnosis, malignant 
hypertension, mass lesion and obstructive hydrocephalus 
should be taken into consideration; however, the most com-
mon causes of papilloedema are idiopathic intracranial hy-
pertension (IHT) and central venous thrombosis (CVT) [29].
Evaluating the blood pressure and tests for proteinuria 
should be conducted to exclude preeclampsia. MRI of the 
brain without contrast is a safe diagnostic procedure after 
18 weeks of pregnancy [31] for detecting mass lesions, hy-
drocephalus or CVT but there are few data confirming the 
safety of MRI without contrast in the first trimester. Due to 
exposure to radiation and a teratogenic effect on the foetus, 
computed tomography (CT) should only be conducted if 
MRI is inaccessible. Proper preventive methods should be 
used to avoid radiation to the foetus. Lumbar puncture (LP) 
is also a possible diagnostic method in pregnant women if 
any contraindications are found after evaluating the MRI or 
CT scans; after obtaining cerebrospinal fluid (CSF) several 
laboratory tests (glucose, cell, protein count, cytology, VDRL, 
cryptococcal antigen) should be conducted.
Treatment depends on diagnosis of the primary disorder 
that leads to papilloedema and must be undertaken to avoid 
loss of optic nerve function. Diuretics, steroids and antico-
agulants are used in the treatment of IHT or CVT. Many of 
these drugs are classified as category C, which is why there 
is always a probable risk of side effects on the foetus [29].
Ocular symptoms of preeclampsia and eclampsia
Blurry vision, photopsia and visual field defects are 
symptoms that may occur in women with eclampsia or 
preeclampsia. Fundoscopy reveals retinal haemorrhages, 
Elschnig spots, macular oedema, cotton wool spots and 
segmented or generalized blood vessel narrowing. In some 
cases, papilloedema or serous retinal detachment is also 
observed [31].
The most crucial for therapy is obtaining an optimal 
blood pressure level. Macular oedema may be treated with 
laser therapy, steroids or anti-VEGF intravitreal injections 
after carefully reviewing the benefits and risks. Serous retinal 
detachment should spontaneously subside after curing the 
underlying disease.
Sheehan’s syndrome
An ocular manifestation of Sheehan’s syndrome can be 
diplopia (double vision), sudden vision loss or visual field 
defects and ophthalmoplegia. Medical history that sug-
gests perinatal haemorrhage requires proper diagnostics 
regarding assessment of thyroid and adrenal gland function, 
level of growth hormone and MRI scan results [32]. Ocular 
symptoms of Sheehan’s syndrome may recede after using 
hydrocortisone [33].
SUMMARY
Ocular disorders in pregnant women are most often 
physiological and transient. However, severe eye disorders 
during pregnancy should always be considered and treated 
in order to avoid serious complications. In patients with 
diabetes, hypertension, glaucoma, papilloedema or retinal 
detachment, constant ophthalmological evaluation is nec-
essary throughout pregnancy.
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